Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > BUSINESS
BUSINESS
- Sandoz to Copromote Somatropin with Nipro Pharma
May 22, 2012
- Towa to Review Existing Products for Improved Competitiveness, Starting with 70 APIs
May 22, 2012
- Chugai to Make CNS Its Strategic Field; 3 Compounds in Pipeline: President Kosaka
May 21, 2012
- Operating Profits Up 4.2%, Business Expansion Slows Down in FY2011: Major Generics Manufacturers
May 21, 2012
- Hisamitsu Files for Transdermal Oxybutynin for Overactive Bladder
May 21, 2012
- The Growing Presence of Foreign-Affiliates (3)
May 21, 2012
- “Confident in Usefulness” of Alogliptin: President Hasegawa of Takeda
May 18, 2012
- Ono to Conduct Joint Research with German Pharmaceutical Company Using Affilin Technology
May 18, 2012
- Ishibashi to Become SSP President, Torii to Be Withdrawn from Presidency
May 18, 2012
- Morishita Jintan, AnGes MG Jointly Research and Develop Oral Vaccine
May 18, 2012
- Pfizer Resubmit NDA for Fesoterodine Fumarate in March
May 18, 2012
- Eisai Sets Domestic Sales Forecast for Aricept at 90 Billion Yen on Impact of Generics
May 17, 2012
- Double-Digit Drop in Sales, Profits Reported Due to Patent Expiration of Aricept: Eisai
May 17, 2012
- Nichi-Iko, sanofi-aventis to Copromote Lipitor Generic Aiming at Cumulative Sales of 10 Billion Yen over 5 Years
May 17, 2012
- Sawai Targets Sales of 100 Billion Yen in FY2014, Gives Up Biosimilars Development: New Midterm Plan
May 17, 2012
- FY2011 Settlement of Accounts: Second-Tier Drug Makers Struggled, Domestic-Focused Mid-Sized Makers Posted Growth
May 17, 2012
- Top Five Drug Makers Report 12.8% Decline in Operating Profits with 3 Reporting Double-Digit Falls in Profits
May 17, 2012
- Final Costs to Be Confirmed by Product, Changing from Manufacturer Basis: Medipal Group
May 16, 2012
- Pivotal Focus for Biosimilars Business on Japan: Daiichi Sankyo President Nakayama
May 16, 2012
- Vedolizumab Achieved Remission in Crohn’s Disease Patients in PIII: Takeda
May 16, 2012
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…